Patents by Inventor Hassan Javanbakht
Hassan Javanbakht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11896648Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R? (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.Type: GrantFiled: October 20, 2021Date of Patent: February 13, 2024Assignee: GILEAD SCIENCES, INC.Inventors: Manuel Baca, Sarah A. Gilmore, Hassan Javanbakht, Prasenjit K. Mukherjee
-
Publication number: 20230331837Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: October 7, 2022Publication date: October 19, 2023Applicant: HOFFMANN-LA ROCHE INC.Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Soren OTTOSEN, Souphalone LUANGSAY
-
Publication number: 20230210887Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis virus (HBV) infection, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a BV infection. The invention also provides for inhibitors of PAPD5 or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.Type: ApplicationFiled: December 22, 2022Publication date: July 6, 2023Applicant: HOFFMANN-LA ROCHE INC.Inventors: Hassan JAVANBAKHT, Soren OTTOSEN, Lykke PEDERSEN, Henrik MUELLER
-
Patent number: 11534452Abstract: A method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection is provided, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. Inhibitors of PAPD5 or PAPD7 are provided for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection.Type: GrantFiled: June 19, 2017Date of Patent: December 27, 2022Assignee: HOFFMANN-LA ROCHE INC.Inventors: Hassan Javanbakht, Søren Ottosen, Lykke Pedersen, Henrik Mueller
-
Patent number: 11466081Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: GrantFiled: August 21, 2020Date of Patent: October 11, 2022Assignee: HOFFMANN-LA ROCHE INC.Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Publication number: 20220125884Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R? (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.Type: ApplicationFiled: October 20, 2021Publication date: April 28, 2022Inventors: Manuel Baca, Sarah A. Gilmore, Magdeleine S. Hung, Hassan Javanbakht, Manu Kanwar, Shahzada Khan, Prasenjit K. Mukherjee, Mark R. Nagel, Giuseppe Papalia, Danny W. Tam, Majlinda K. Thomas
-
Publication number: 20220096527Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits hepatitis B virus (HBV) infections. The compound (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; and is identified as a compound that prevents, ameliorates and/or inhibits HBV infections. An inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing HBV infections; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of HBV infections is also provided. The present invention includes a 10-pharmaceutical composition for use in treatment and/or prevention of HBV infections, and a method for monitoring therapeutic success during treatment of HBV infections.Type: ApplicationFiled: December 3, 2021Publication date: March 31, 2022Applicant: HOFFMANN-LA ROCHE INC.Inventors: Xingchun HAN, Hassan JAVANBAKHT, Henrik MUELLER, Yongguang WANG, Song YANG
-
Patent number: 11191775Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for an inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a 10 pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.Type: GrantFiled: June 19, 2017Date of Patent: December 7, 2021Assignee: HOFFMANN-LA ROCHE INC.Inventors: Xingchun Han, Hassan Javanbakht, Henrik Mueller, Yongguang Wang, Song Yang
-
Publication number: 20210147535Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: August 21, 2020Publication date: May 20, 2021Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Søren OTTOSEN, Souphalone LUANGSAY
-
Patent number: 10829555Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: GrantFiled: April 2, 2020Date of Patent: November 10, 2020Assignee: Hoffman-La Roche Inc.Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Patent number: 10745480Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: GrantFiled: October 25, 2019Date of Patent: August 18, 2020Assignee: Hoffmann-La Roche, Inc.Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Publication number: 20200247884Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: April 2, 2020Publication date: August 6, 2020Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Søren OTTOSEN, Souphalone LUANGSAY
-
Publication number: 20200048344Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: October 25, 2019Publication date: February 13, 2020Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Publication number: 20190216846Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for inhibitors of PAPD5 or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.Type: ApplicationFiled: June 19, 2017Publication date: July 18, 2019Applicant: HOFFMANN-LA ROCHE INC.Inventors: Hassan JAVANBAKHT, Søren OTTOSEN, Lykke PEDERSEN, Henrik MUELLER
-
Publication number: 20190194768Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for an inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a 10 pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.Type: ApplicationFiled: June 19, 2017Publication date: June 27, 2019Applicant: HOFFMANN-LA ROCHE INC.Inventors: Xingchun HAN, Hassan JAVANBAKHT, Henrik MUELLER, Yongguang WANG, Song YANG
-
Patent number: 9949966Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: June 21, 2016Date of Patent: April 24, 2018Assignee: Hoffman-La Roche Inc.Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou
-
Publication number: 20170283496Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: March 14, 2017Publication date: October 5, 2017Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Publication number: 20160296515Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: June 21, 2016Publication date: October 13, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou
-
Patent number: 9458153Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: January 30, 2015Date of Patent: October 4, 2016Assignee: Hoffmann-La Roche INC.Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou
-
Publication number: 20160207914Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: January 30, 2015Publication date: July 21, 2016Applicant: HOFFMANN-LA ROCHE INC.Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou